|
Palo Alto, Calif. -- June 21, 2004--Researchers across the world are working toward biocompatibility by optimizing interactions that occur between implanted biomaterials and the host living tissue. Overcoming this significant technical challenge is likely to broaden the scope of biomaterials' applications.
"Thrombosis involving blood coagulation and adhesion of blood platelets to biomaterial surfaces as well as fibrous-tissue encapsulation of biomaterials that are implanted in soft tissues are two challenging issues for researchers in quest of biocompatibility," says Technical Insights Analyst Dr. James Smith.
Biocompatibility assumes greater significance as surgeons are increasingly focusing on treatment of chronic diseases.
For instance, spinal surgeons are turning their attention to technologies that can treat chronic back pain rather than focusing on achieving spinal stability, as fusion technology such as cages, bone grafts, and fixation devices attain maturity in terms of providing positive clinical benefits.
Growing understanding of complex biological materials and development of novel biomaterials designed at the molecular level to meet specific medical applications are likely to mark future advancements toward biocompatibility.
One such development is tailor-made, designer polymers from a beaker by programming the modular polymer scaffolds to attract building blocks of small molecules. This 'one-beaker' process aims at simplifying the synthesis of designer polymers through self-assembly using combinatorial chemistry.
Researchers have used the same 'one-beaker' principle to build copolymers and modify properties of polymers by changing certain variables such as temperature, pH factor, ultraviolet light, and solvents.
Other exciting research prospects include the development of customized organic polymers that can be used to regenerate damaged nerves. Research on visual prostheses promises to restore vision for blind individuals by way of retinal implants.
However, researchers may have to face long periods of product testing, product cycle, and clinician acceptance while countering reimbursement issues before successful commercialization.
"The efforts of researchers are hampered by the current liability laws and stringent functioning of the Food and Drug Administration (FDA) in certifying the safety and effectiveness of the medical devices based on the results of clinical trials," informs Smith.
However, the FDA's conservative policy and demand for comprehensive documentation is understandable, as medical device manufacturers can be subject to liability lawsuits even after obtaining governmental approval.
Advances in Biomaterials, part of the Healthcare Vertical Subscription Service, provides valuable insights into this exciting industry by segmenting the research into three categories: synthetic polymers (plastics), natural polymers (biomolecular materials), and inorganic materials (metals, alloys, ceramic, glass). The study summarizes the efforts of researchers in developing 'designer' biomaterials while providing detailed discussions on their properties, particularly on their use as coatings and other surface characteristics. Interviews and Executive Summaries are available to the press.
If you are interested in an analysis overview which provide manufacturers, end-users and other industry participants an overview, summary, challenges and latest coverage of Advances in Biomaterials - then send an email to Julia Paulson – North American Corporate Communications at jpaulson@frost.com with the following information: Full name, Company Name, Title, Contact Tel Number, Contact Fax Number, Email. Upon receipt of the above information, an overview will be emailed to you.
Technical Insights is an international technology analysis business that produces a variety of technical news alert, newsletter, and report services.
Frost & Sullivan, an international growth consultancy, has been supporting clients' expansion for more than four decades. Our market expertise covers a broad spectrum of industries, while our portfolio of advisory competencies includes custom strategic consulting, market intelligence and management training. Our mission is to forge partnerships with our clients' management teams to deliver market insights and to create value and drive growth through innovative approaches. Frost & Sullivan's network of consultants, industry experts, corporate trainers and support staff, spans the globe with offices in every major country.
Advances in Biomaterials
D272
Contact:
USA:
Julia Paulson
P: 210.247.3870
F: 210.348.1003
E: jpaulson@frost.com
Europe
Katja Feick
P: +44 (0) 20 7915 7856
F: +44 (0) 20 7730 3343
E: katja.feick@frost.com
APAC:
Pramila Gurtoo
DID: (603) 6204 5811
Gen: (603) 6204 5800
Fax: (603) 6201 7402
E: pgurtoo@frost.com
www.frost.com
www.Technical-Insights.frost.com
Keywords in this release: Biomaterials, applications, biocompatibility, implanted biomaterials, host living tissue, thrombosis, blood coagulation, adhesion, blood platelets, biomaterial surfaces, fibrous-tissue encapsulation, soft tissues, chronic diseases, spinal surgeons, chronic back pain, spinal stability, fusion technology, cages, bone grafts, fixation devices, clinical benefits, biological materials, molecular level, designer polymers, modular polymer scaffolds, 'one-beaker' process, synthesis, self-assembly, combinatorial chemistry, copolymers, customized organic polymers, visual prostheses, retinal implants, reimbursement issues, liability laws, Food and Drug Administration, FDA, clinical trials